The final draft guidance issued by NICE means that patients will be eligible to receive the antifibrotic treatment, which is currently recommended for patients with a FVC value of 50% to 80% predicted, earlier in the course of their disease.
The recommendation follows clinical trial evidence demonstrating that Ofev slows the decline of lung function compared with placebo in patients with IPF with an FVC above 80%, with long-term evidence suggesting that this effect is maintained over time…
